Overview

Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Patients with advanced breast cancer to receive sunitinib (Sutent) once daily until disease progression.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Sunitinib